Besides anti-BRAF/MEK targeted therapies, the recent discovery that immune checkpoint inhibitors, targeting regulatory molecules on T lymphocytes (anti-CTLA4, anti-PD-1, and anti-PD-L1), are highly efficient in melanoma patients has revolutionized the treatment of metastatic melanoma. This evidence concerns the gene BRAF and melanoma.